Canada Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pain Medication, Hormonal Suppression Therapy), By Drug Class, By Route Of Administration, By Distribution Channel, By State, And Segment Forecasts, 2025 - 2033

October 2025 | 150 pages | ID: CE922211DA63EN
Grand View Research, Inc.

Abstracts

The Canada endometriosis treatment market size was estimated at USD 53.58 million in 2024 and is projected to reach USD 156.71 million by 2033, growing at a CAGR of 13.26% from 2025 to 2033. The growth is driven by increasing awareness, advancements in treatment options, improved healthcare access, and rising demand for effective endometriosis management solutions, contributing to significant growth across all segments.

Endometriosis affects approximately 10% of Canadian women of reproductive age, equating to hundreds of thousands of individuals experiencing chronic pelvic pain, painful menstruation, and fertility challenges. This significant prevalence has created a substantial demand for effective treatment options across Canada, including hormonal therapies, non-hormonal pain management, and surgical interventions. Growing awareness among Canadian healthcare providers and patients has led to earlier diagnosis and treatment, expanding the utilization of existing therapies while encouraging the adoption of innovative treatments within the Canadian market.

The chronic and recurring nature of endometriosis in Canada drives ongoing treatment requirements. Women often need long-term management through GnRH agonists/antagonists, oral contraceptives, and minimally invasive surgical procedures. Canadian healthcare systems are responding by increasing access to specialized care and approved therapies. Rising patient consultations and prescription rates contribute to steady market growth, particularly for pharmaceutical companies offering solutions in women’s health. The continued demand for effective symptom relief and fertility preservation directly strengthens the Canada endometriosis treatment industry.

High prevalence also attracts pharmaceutical investment and innovation in Canada. With a significant patient population, the country represents an important market for emerging therapies such as oral GnRH antagonists, selective progesterone receptor modulators, and combination hormone treatments. Clinical trials conducted in Canadian healthcare settings generate robust local data, supporting the adoption of new therapies. Pharmaceutical companies actively pursue regulatory approval and commercialization in Canada, directly linking the prevalence of endometriosis to research, development, and market expansion of advanced treatment options.

Awareness about endometriosis has significantly increased across Canada due to the proactive efforts of patient advocacy groups and healthcare organizations. Groups such as Endometriosis Network Canada organize workshops, seminars, and educational programs to inform women about symptoms, complications, and available treatment options. These initiatives provide patients with resources to understand their condition, recognize early signs, and seek timely medical care. By addressing common misconceptions and reducing social stigma around menstrual and reproductive health, these programs empower women to discuss their symptoms openly with healthcare providers, leading to earlier diagnosis and improved management of the disease.

Canada Endometriosis Treatment Market Report Segmentation

This report forecasts revenue growth at the state level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Canada endometriosis treatment market report based on drug class, treatment type, route of administration, distribution channel, and state:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• NSAIDs (Analgesics)
• Combined Oral Contraceptives (COCs)
• Progestins - Oral
• GnRH Modulators
• GnRH Agonists - Injectable depot (SC/IM)
• GnRH Antagonists - Oral
• Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pain Medication
• Hormonal Suppression Therapy
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacy
• Hospital Pharmacy
• Others
• State Outlook (Revenue, USD Million, 2021 - 2033)
• Canada
• Ontario
• Quebec
• British Columbia
• Alberta
• Rest of Canada

This report can be delivered to the clients within 3 Business Days

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

1.1. Market Segmentation & Scope
1.2. Segment Definitions
  1.2.1. Drug Class
  1.2.2. Treatment Type
  1.2.3. Route of Administration
  1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
  1.5.1. Purchased Database
  1.5.2. GVR’s Internal Database
  1.5.3. Secondary Sources
  1.5.4. Primary Research
1.6. Information Analysis
  1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
  1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

CHAPTER 3. CANADA ENDOMETRIOSIS TREATMENT MARKET VARIABLES, TRENDS, & SCOPE

3.1. Market Lineage Outlook
3.2. Market Dynamics
  3.2.1. Market Driver Analysis
  3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
  3.3.1. Industry Analysis - Porter’s Five Forces Analysis
    3.3.1.1. Supplier Power
    3.3.1.2. Buyer Power
    3.3.1.3. Substitution Threat
    3.3.1.4. Threat of New Entrants
    3.3.1.5. Competitive Rivalry
  3.3.2. PESTLE Analysis

CHAPTER 4. CANADA ENDOMETRIOSIS TREATMENT MARKET: DRUG CLASS BUSINESS ANALYSIS

4.1. Drug Class Market Share, 2024 & 2033
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
4.4. NSAIDs (Analgesics)
  4.4.1. NSAIDs (Analgesics) Market, 2021 - 2033 (USD Million)
4.5. Combined Oral Contraceptives (COCs)
  4.5.1. Combined Oral Contraceptives (COCs) Market, 2021 - 2033 (USD Million)
4.6. Progestins - Oral
  4.6.1. Progestins - Oral Market, 2021 - 2033 (USD Million)
4.7. GnRH Modulators
  4.7.1. GnRH Modulators Market, 2021 - 2033 (USD Million)
  4.7.2. GnRH Agonists - Injectable depot (SC/IM)
    4.7.2.1. GnRH Agonists - Injectable depot (SC/IM) Market, 2021 - 2033 (USD Million)
    4.7.2.2. GnRH Antagonists - Oral Market, 2021 - 2033 (USD Million)

CHAPTER 5. CANADA ENDOMETRIOSIS TREATMENT MARKET: TREATMENT TYPE BUSINESS ANALYSIS

5.1. Treatment Type Market Share, 2024 & 2033
5.2. Treatment Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
5.4. Pain Medication
  5.4.1. Pain Medication Market, 2021 - 2033 (USD Million)
5.5. Hormonal Suppression Therapy
  5.5.1. Hormonal Suppression Therapy Market, 2021 - 2033 (USD Million)

CHAPTER 6. CANADA ENDOMETRIOSIS TREATMENT MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS

6.1. Route of Administration Market Share, 2024 & 2033
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
6.4. Injectable
  6.4.1. Injectable Market, 2021 - 2033 (USD Million)
6.5. Oral
  6.5.1. Oral Market, 2021 - 2033 (USD Million)

CHAPTER 7. CANADA ENDOMETRIOSIS TREATMENT MARKET: DISTRIBUTION CHANNEL BUSINESS ANALYSIS

7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
7.4. Retail Pharmacy
  7.4.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
7.5. Hospital Pharmacy
  7.5.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
7.6. Others
  7.6.1. Others Market, 2021 - 2033 (USD Million)

CHAPTER 8. CANADA ENDOMETRIOSIS TREATMENT MARKET: STATE ESTIMATES & TREND ANALYSIS

8.1. State Market Share Analysis, 2024 & 2033
8.2. State Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. Ontario
  8.4.1. Competitive Scenario
  8.4.2. Regulatory Framework
  8.4.3. Reimbursement Framework
  8.4.4. Ontario Endometriosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Quebec
  8.5.1. Competitive Scenario
  8.5.2. Regulatory Framework
  8.5.3. Reimbursement Framework
  8.5.4. Quebec Endometriosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. British Columbia
  8.6.1. Competitive Scenario
  8.6.2. Regulatory Framework
  8.6.3. Reimbursement Framework
  8.6.4. British Columbia Endometriosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Alberta
  8.7.1. Competitive Scenario
  8.7.2. Regulatory Framework
  8.7.3. Reimbursement Framework
  8.7.4. Alberta Endometriosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Rest of Canada
  8.8.1. Competitive Scenario
  8.8.2. Regulatory Framework
  8.8.3. Reimbursement Framework
  8.8.4. Rest of Canada Endometriosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 9. COMPETITIVE LANDSCAPE

9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
  9.5.1. AbbVie Inc.
    9.5.1.1. Overview
    9.5.1.2. Financial Performance
    9.5.1.3. Product Benchmarking
    9.5.1.4. Strategic Initiatives
  9.5.2. Bayer AG
    9.5.2.1. Overview
    9.5.2.2. Financial Performance
    9.5.2.3. Product Benchmarking
    9.5.2.4. Strategic Initiatives
  9.5.3. TerSera Therapeutics
    9.5.3.1. Overview
    9.5.3.2. Financial Performance
    9.5.3.3. Product Benchmarking
    9.5.3.4. Strategic Initiatives
  9.5.4. Sumitomo Pharma / Myovant
    9.5.4.1. Overview
    9.5.4.2. Financial Performance
    9.5.4.3. Product Benchmarking
    9.5.4.4. Strategic Initiatives
  9.5.5. Pfizer Inc.
    9.5.5.1. Overview
    9.5.5.2. Financial Performance
    9.5.5.3. Product Benchmarking
    9.5.5.4. Strategic Initiatives
  9.5.6. Knight Therapeutics
    9.5.6.1. Overview
    9.5.6.2. Financial Performance
    9.5.6.3. Product Benchmarking
    9.5.6.4. Strategic Initiatives
  9.5.7. Searchlight Pharma
    9.5.7.1. Overview
    9.5.7.2. Financial Performance
    9.5.7.3. Product Benchmarking
    9.5.7.4. Strategic Initiatives
  9.5.8. Apotex Inc.
    9.5.8.1. Overview
    9.5.8.2. Financial Performance
    9.5.8.3. Product Benchmarking
    9.5.8.4. Strategic Initiatives
  9.5.9. Teva Canada Limited
    9.5.9.1. Overview
    9.5.9.2. Financial Performance
    9.5.9.3. Product Benchmarking
    9.5.9.4. Strategic Initiatives
  9.5.10. Sandoz Group AG
    9.5.10.1. Overview
    9.5.10.2. Financial Performance
    9.5.10.3. Product Benchmarking
    9.5.10.4. Strategic Initiatives

List Of Tables

LIST OF TABLES

Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Canada endometriosis treatment market, by State, 2021 - 2033 (USD Million)
Table 4. Canada endometriosis treatment market, by drug class, 2021 - 2033 (USD Million)
Table 5. Canada endometriosis treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 6. Canada endometriosis treatment market, by route of administration, 2021 - 2033 (USD Million)
Table 7. Canada endometriosis treatment market, by distribution channel, 2021 - 2033 (USD Million)
Table 8. Ontario endometriosis treatment market, by drug class, 2021 - 2033 (USD Million)
Table 9. Ontario endometriosis treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 10. Ontario endometriosis treatment market, by route of administration, 2021 - 2033 (USD Million)
Table 11. Ontario endometriosis treatment market, by distribution channel, 2021 - 2033 (USD Million)
Table 12. Quebec endometriosis treatment market, by drug class, 2021 - 2033 (USD Million)
Table 13. Quebec endometriosis treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 14. Quebec endometriosis treatment market, by route of administration, 2021 - 2033 (USD Million)
Table 15. Quebec endometriosis treatment market, by distribution channel, 2021 - 2033 (USD Million)
Table 16. British Columbia endometriosis treatment market, by drug class, 2021 - 2033 (USD Million)
Table 17. British Columbia endometriosis treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 18. British Columbia endometriosis treatment market, by route of administration, 2021 - 2033 (USD Million)
Table 19. British Columbia endometriosis treatment market, by distribution channel, 2021 - 2033 (USD Million)
Table 20. Alberta endometriosis treatment market, by drug class, 2021 - 2033 (USD Million)
Table 21. Alberta endometriosis treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 22. Alberta endometriosis treatment market, by route of administration, 2021 - 2033 (USD Million)
Table 23. Alberta endometriosis treatment market, by distribution channel, 2021 - 2033 (USD Million)
Table 24. Rest of Canada endometriosis treatment market, by drug class, 2021 - 2033 (USD Million)
Table 25. Rest of Canada endometriosis treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 26. Rest of Canada endometriosis treatment market, by route of administration, 2021 - 2033 (USD Million)
Table 27. Rest of Canada endometriosis treatment market, by distribution channel, 2021 - 2033 (USD Million)

List Of Figures

LIST OF FIGURES

Fig. 1 Canada Endometriosis Treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Drug Class and Treatment Type Segment snapshot
Fig. 10 Route of Administration and Distribution Channel Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market (USD Billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE Analysis
Fig. 16 Canada endometriosis treatments market: Drug class outlook and key takeaways
Fig. 17 Canada endometriosis treatments market: Drug class movement analysis
Fig. 18 NSAIDs (Analgesics) Canada endometriosis treatments market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 19 Combined Oral Contraceptives (COCs) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 20 Progestins oral market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 21 GnRH Modulators market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 22 GnRH Agonists market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 23 Goserelin (Zoladex) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 24 Leuprolide (Lupron Depot) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 25 Triptorelin (Trelstar) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 26 GnRH Antagonist Oral market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 27 Elagolix (Orilissa) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 28 Relugolix combo (Myfembree) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 29 Canada Endometriosis Treatments market: Treatment Type outlook and key takeaways
Fig. 30 Canada Endometriosis Treatments market: Treatment type movement analysis
Fig. 31 Pain medication endometriosis treatments market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 32 Hormonal suppression therapy endometriosis treatments market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 33 Canada Endometriosis Treatments market: Route of administration outlook and key takeaways
Fig. 34 Canada Endometriosis Treatments market: Route of administration movement analysis
Fig. 35 Oral market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 36 Injectable market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 37 Canada Endometriosis Treatments market: Distribution channel outlook and key takeaways
Fig. 38 Canada Endometriosis Treatments market: Distribution Channel movement analysis
Fig. 39 Hospital pharmacy market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 40 Retail pharmacy market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 41 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 Canada endometriosis treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Ontario endometriosis treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 45 Ontario endometriosis treatment market GnRH Agonists (Goserelin (Zoladex)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 46 Ontario endometriosis treatment market GnRH Agonists (Leuprolide (Lupron Depot)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 47 Ontario endometriosis treatment market GnRH Agonists (Triptorelin (Trelstar)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Ontario endometriosis treatment market GnRH Antagonists (Elagolix (Orilissa)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 49 Ontario endometriosis treatment market GnRH Antagonists (Relugolix combo (Myfembree)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 50 Quebec endometriosis treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 51 Quebec endometriosis treatment market GnRH Agonists (Goserelin (Zoladex)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 52 Quebec endometriosis treatment market GnRH Agonists (Leuprolide (Lupron Depot)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 53 Quebec endometriosis treatment market GnRH Agonists (Triptorelin (Trelstar)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 54 Quebec endometriosis treatment market GnRH Antagonists (Elagolix (Orilissa)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 55 Quebec endometriosis treatment market GnRH Antagonists (Relugolix combo (Myfembree)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 56 British Columbia endometriosis treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 57 British Columbia endometriosis treatment market GnRH Agonists (Goserelin (Zoladex)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 58 British Columbia endometriosis treatment market GnRH Agonists (Leuprolide (Lupron Depot)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 59 British Columbia endometriosis treatment market GnRH Agonists (Triptorelin (Trelstar)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 60 British Columbia endometriosis treatment market GnRH Antagonists (Elagolix (Orilissa)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 61 British Columbia endometriosis treatment market GnRH Antagonists (Relugolix combo (Myfembree)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 62 Alberta endometriosis treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 63 Alberta endometriosis treatment market GnRH Agonists (Goserelin (Zoladex)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 64 Alberta endometriosis treatment market GnRH Agonists (Leuprolide (Lupron Depot)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 65 Alberta endometriosis treatment market GnRH Agonists (Triptorelin (Trelstar)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 66 Alberta endometriosis treatment market GnRH Antagonists (Elagolix (Orilissa)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 67 Alberta endometriosis treatment market GnRH Antagonists (Relugolix combo (Myfembree)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 68 Rest of Canada (ROC) endometriosis treatment market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 69 Rest of Canada endometriosis treatment market GnRH Agonists (Goserelin (Zoladex)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 70 Rest of Canada endometriosis treatment market GnRH Agonists (Leuprolide (Lupron Depot)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 71 Rest of Canada endometriosis treatment market GnRH Agonists (Triptorelin (Trelstar)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 72 Rest of Canada endometriosis treatment market GnRH Antagonists (Elagolix (Orilissa)) estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 73 Rest of Canada endometriosis treatment market GnRH Antagonists (Relugolix combo (Myfembree)) estimates and forecasts, 2021 - 2033 (USD Million)